Toxicological assessment of drugs that affect the endocrine system in puberty-related disorders

Bibliography

• Maranghi F, Mantovani A. Targeted toxicological testing to investigate the role of endocrine disrupters in puberty disorders. Reprod Toxic Elmsford N 2012;33(3):290-6
   PubMed Web of Science ®Google Scholar
• Diamanti-Kandarakis E, Gore AC. Introduction to endocrine disruptors and puberty. In: Diamanti-Kandarakis E, Gore AC, editors. Disruptors puberty [Internet]. Humana Press; Totowa, NJ: 2012. p. 1-8. Available from: http://rd.springer.com/chapter/10.1007/978-1-60761-561-3_4
   Google Scholar
• Garry VF, Truran P. Secular Trends in Pubertal Timing: A Role for Environmental Chemical Exposure? In: Diamanti-Kandarakis E, Gore AC, Editors Disruptors puberty [Internet]. Humana Press; Totowa, NJ: 2012. p. 357-72
   Google Scholar
• Walvoord EC. The timing of puberty: is it changing? Does it matter? J Adolesc Heal Off
   Google Scholar
• Euling SY, Selevan SG, Pescovitz OH, Skakkebaek NE. Role of environmental factors in the timing of puberty. Pediatrics 2008;121(3):S167-71
   PubMedGoogle Scholar
• Toppari J, Juul A. Trends in puberty timing in humans and environmental modifiers. Mol Cell Endocrinol 2010;324(1-2):39-44
   PubMed Web of Science ®Google Scholar
• Fenichel P. Delayed puberty. Endocr Dev 2012;22:138-59
   PubMedGoogle Scholar
• Deligeoroglou E, Tsimaris P. Menstrual disturbances in puberty. Best Pract Res Clin Obstet Gynaecol 2010;24:2:157-71
   PubMed Web of Science ®Google Scholar
• Backes M, Zwaveling-Soonawala N, Kamp GA. Premature pubarche is not always an innocent phenomenon. Ned Tijdschr Geneeskd 2012;156(43):A5147
   PubMedGoogle Scholar
• Lenz AM, Shulman D, Eugster EA, et al. Bicalutamide and third-generation aromatase inhibitors in testotoxicosis. Pediatrics 2010;126(3):e728-33
   PubMed Web of Science ®Google Scholar
• Isidori AM, Giannetta E, Lenzi A. Male hypogonadism. Pituitary 2008;11(2):171-80
   PubMed Web of Science ®Google Scholar
• Umławska W, Krzyzanowska M. Puberty in certain chronic illness. Pediatr Endocrinol Diabetes Metab 2009;15(7):216-18
   PubMedGoogle Scholar
• Wolthers OD. Growth problems in children with asthma. Horm Res 2002;57(Suppl 2):83-7
   PubMedGoogle Scholar
• Brand PL. Inhaled corticosteroids reduce growth. Or do they? Eur Respir J Off J Eur Soc Clin Respir Physiol 2001;17(2):287-94
   PubMed Web of Science ®Google Scholar
• Drosdzol A, Skrzypulec V, Wilk K, Nowosielski K. The influence of bronchial asthma on sexual maturation of girls. J Physiol Pharmacol Off J Pol Physiol Soc 2007;58(Suppl 5(Pt 1)):155-63
   PubMedGoogle Scholar
• Schultz R, Isola J, Parvinen M, et al. Localization of the glucocorticoid receptor in testis and accessory sexual organs of male rat. Mol Cell Endocrinol 1993;95(1-2):115-20
   PubMed Web of Science ®Google Scholar
• Tetsuka M, Milne M, Simpson GE, Hillier SG. Expression of 11beta-hydroxysteroid dehydrogenase, glucocorticoid receptor, and mineralocorticoid receptor genes in rat ovary. Biol Reprod 1999;60(2):330-5
   PubMed Web of Science ®Google Scholar
• Bambino TH, Hsueh AJ. Direct inhibitory effect of glucocorticoids upon testicular luteinizing hormone receptor and steroidogenesis in vivo and in vitro. Endocrinology 1981;108(6):2142-8
   PubMed Web of Science ®Google Scholar
• Hsueh AJ, Erickson GF. Glucocorticoid inhibition of FSH-induced estrogen production in cultured rat granulosa cells. Steroids 1978;32(5):639-48
   PubMed Web of Science ®Google Scholar
• Ozkaya E, Nursoy MA, Uzuner S, et al. Osteocalcin, cortisol levels, and bone mineral density in prepubertal children with asthma treated with long-term fluticasone propionate. Horm Res Pædiatrics 2012;77(6):351-7
   PubMed Web of Science ®Google Scholar
• De Benedictis FM, Teper A, Green RJ, et al. Effects of 2 inhaled corticosteroids on growth: results of a randomized controlled trial. Arch Pediatr Adolesc Med 2001;155(11):1248-54
   PubMed Web of Science ®Google Scholar
• Baraniuk JN, Murray J. The linear relationship between changes in childhood growth velocity and topical glucocorticoid dose. Allergy Asthma Proc Off J Reg State Allergy Soc 2001;22(3):153-64
   PubMed Web of Science ®Google Scholar
• Daley-Yates PT, Richards DH. Relationship between systemic corticosteroid exposure and growth velocity: development and validation of a pharmacokinetic/pharmacodynamic model. Clin Ther 2004;26(11):1905-19
   PubMed Web of Science ®Google Scholar
• Benchimol EI, Fortinsky KJ, Gozdyra P, et al. Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends. Inflamm Bowel Dis 2011;17(1):423-39
   PubMed Web of Science ®Google Scholar
• Griffiths AM. Specificities of inflammatory bowel disease in childhood. Best Pract Res Clin Gastroenterol 2004;18(3):509-23
   PubMed Web of Science ®Google Scholar
• Ezri J, Marques-Vidal P, Nydegger A. Impact of disease and treatments on growth and puberty of pediatric patients with inflammatory bowel disease. Digestion 2012;85(4):308-19
   PubMed Web of Science ®Google Scholar
• Ballinger AB, Savage MO, Sanderson IR. Delayed puberty associated with inflammatory bowel disease. Pediatr Res 2003;53(2):205-10
   PubMed Web of Science ®Google Scholar
• Azooz OG, Farthing MJ, Savage MO, Ballinger AB. Delayed puberty and response to testosterone in a rat model of colitis. Am J Physiol Regul Integr Comp Physiol 2001;281(5):R1483-91
   PubMed Web of Science ®Google Scholar
• Heuschkel R, Salvestrini C, Beattie RM, et al. Guidelines for the management of growth failure in childhood inflammatory bowel disease. Inflamm Bowel Dis 2008;14(6):839-49
   PubMed Web of Science ®Google Scholar
• Pfefferkorn M, Burke G, Griffiths A, et al. Growth abnormalities persist in newly diagnosed children with crohn disease despite current treatment paradigms. J Pediatr Gastroenterol Nutr 2009;48(2):168-74
   PubMed Web of Science ®Google Scholar
• Walters TD, Gilman AR, Griffiths AM. Linear growth improves during infliximab therapy in children with chronically active severe Crohn's disease. Inflamm Bowel Dis 2007;13(4):424-30
   PubMed Web of Science ®Google Scholar
• Mason A, Malik S, Russell RK, et al. Impact of inflammatory bowel disease on pubertal growth. Horm Res Pædiatr 2011;76(5):293-9
   PubMed Web of Science ®Google Scholar
• Grossman AB, Baldassano RN. Specific considerations in the treatment of pediatric inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2008;2(1):105-24
   PubMedGoogle Scholar
• Giustina A, Wehrenberg WB. The role of glucocorticoids in the regulation of Growth Hormone secretion: mechanisms and clinical significance. Trends Endocrinol Metab Tem 1992;3(8):306-11
   PubMed Web of Science ®Google Scholar
• Griffiths AM. Growth retardation in early-onset inflammatory bowel disease: should we monitor and treat these patients differently? Dig Dis Basel Switz 2009;27(3):404-11
   PubMed Web of Science ®Google Scholar
• Turner D, Levine A, Escher JC, et al. Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines. J Pediatr Gastroenterol Nutr 2012;55(3):340-61
   PubMed Web of Science ®Google Scholar
• Becker AL, Epperson CN. Female puberty: clinical implications for the use of prolactin-modulating psychotropics. Child Adolesc Psychiatr Clin N Am 2006;15(1):207-20
   PubMed Web of Science ®Google Scholar
• Roke Y, van Harten PN, Buitelaar JK, et al. Antipsychotic-induced hyperprolactinemia and testosterone levels in boys. Horm Res Paediatr 2012;77(4):235-40
   PubMed Web of Science ®Google Scholar
• Roke Y, Buitelaar JK, Boot AM, et al. Risk of hyperprolactinemia and sexual side effects in males 10-20 years old diagnosed with autism spectrum disorders or disruptive behavior disorder and treated with risperidone. J Child Adolesc Psychopharmacol 2012;22(6):432-9
   PubMed Web of Science ®Google Scholar
• Correll CU. Effect of hyperprolactinemia during development in children and adolescents. J Clin Psychiatry 2008;69(8):e24
   PubMedGoogle Scholar
• Holzer L, Eap CB. Risperidone-induced symptomatic hyperprolactinaemia in adolescents. J Clin Psychopharmacol 2006;26(2):167-71
   PubMed Web of Science ®Google Scholar
• Alfaro CL, Wudarsky M, Nicolson R, et al. Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine. J Child Adolesc Psychopharmacol 2002;12(2):83-91
   PubMed Web of Science ®Google Scholar
• Arya DK. Extrapyramidal symptoms with selective serotonin reuptake inhibitors. Br J Psychiat 1994;165(6):728-33
   PubMedGoogle Scholar
• Legro RS, Lin HM, Demers LM, Lloyd T. Rapid maturation of the reproductive axis during perimenarche independent of body composition. J Clin Endocrinol Metab 2000;85(3):1021-5
   PubMed Web of Science ®Google Scholar
• Naidoo U, Goff DC, Klibanski A. Hyperprolactinemia and bone mineral density: the potential impact of antipsychotic agents. Psychoneuroendocrinology 2003;28(Suppl 2):97-108
   PubMed Web of Science ®Google Scholar
• Findling RL, Kusumakar V, Daneman D, et al. Prolactin levels during long-term risperidone treatment in children and adolescents. J Clin Psychiatry 2003;64(11):1362-9
   Google Scholar
• Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003;61(2-3):123-36
   PubMed Web of Science ®Google Scholar
• Mallikaarjun S, Salazar DE, Bramer SL. Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. J Clin Pharmacol 2004;44(2):179-87
   PubMed Web of Science ®Google Scholar
• David SR, Taylor CC, Kinon BJ, Breier A. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin Ther 2000;22(9):1085-96
   PubMed Web of Science ®Google Scholar
• Citrome L. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic. Int J Clin Pract 2011;65(2):189-210
   PubMed Web of Science ®Google Scholar
• Reis RM, de Angelo AG, Sakamoto AC, et al. Altered sexual and reproductive functions in epileptic men taking carbamazepine. J Sex Med 2013;10(2):493-9
   PubMed Web of Science ®Google Scholar
• Walker JJ, Terry JR, Tsaneva-Atanasova K, et al. Encoding and decoding mechanisms of pulsatile hormone secretion. J Neuroendocrinol 2010;22(12):1226-38
   PubMed Web of Science ®Google Scholar
• Wang B, Zhou S-F. Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem 2009;16(31):4066-218
   PubMed Web of Science ®Google Scholar
• Beastall GH, Cowan RA, Gray JM, Fogelman I. Hormone binding globulins and anticonvulsant therapy. Scott Med J 1985;30(2):101-5
   PubMed Web of Science ®Google Scholar
• Brion L, Gorostizaga A, Gómez NV, et al. Valproic acid alters mitochondrial cholesterol transport in Y1 adrenocortical cells. Toxicol Vitro Int J Publ Assoc Bibra 2011;25(1):7-12
   PubMed Web of Science ®Google Scholar
• Cerveny L, Svecova L, Anzenbacherova E, et al. Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways. Drug Metab Dispos Biol Fate Chem 2007;35(7):1032-41
   PubMed Web of Science ®Google Scholar
• De Oliva SU, Miraglia SM. Carbamazepine damage to rat spermatogenesis in different sexual developmental phases. Int J Androl 2009;32(5):563-74
   PubMed Web of Science ®Google Scholar
• Oliva SU, Scarano WR, Okada FK, Miraglia SM. Harmful effects of carbamazepine on the postnatal development of the rat ventral prostate. Reprod Biol Endocrinol Rbe 2012;10:22
   PubMedGoogle Scholar
• Mikkonen K, Tapanainen P, Pakarinen AJ, et al. Serum androgen levels and testicular structure during pubertal maturation in male subjects with epilepsy. Epilepsia 2004;45(7):769-76
   PubMed Web of Science ®Google Scholar
• Verrotti A, Loiacono G, Laus M, et al. Hormonal and reproductive disturbances in epileptic male patients: emerging issues. Reprod Toxicol Elmsford N 2011;31(4):519-27
   PubMed Web of Science ®Google Scholar
• El-Khayat HA, Abd El-Basset FZ, Tomoum HY, et al. Physical growth and endocrinal disorders during pubertal maturation in girls with epilepsy. Epilepsia 2004;45(9):1106-15
   PubMed Web of Science ®Google Scholar
• Rättyä J, Vainionpää L, Knip M, et al. The effects of valproate, carbamazepine, and oxcarbazepine on growth and sexual maturation in girls with epilepsy. Pediatrics 1999;103(3):588-93
   PubMed Web of Science ®Google Scholar
• Verrotti A, D'Egidio C, Mohn A, et al. Antiepileptic drugs, sex hormones, and PCOS. Epilepsia 2011;52(2):199-211
   PubMed Web of Science ®Google Scholar
• Cansu A, Yesilkaya E, Serdaroglu A, et al. The effects of oxcarbazepine and valproate therapies on growth in children with epilepsy. Endocr Res 2012;37(4):163-74
   PubMed Web of Science ®Google Scholar
• Prodam F, Bellone S, Casara G, et al. Ghrelin levels are reduced in prepubertal epileptic children under treatment with carbamazepine or valproic acid. Epilepsia 2010;51(2):312-15
   PubMed Web of Science ®Google Scholar
• Holland KD, Monahan S, Morita D, et al. Valproate in children with newly diagnosed idiopathic generalized epilepsy. Acta Neurol Scand 2010;121(3):149-53
   PubMed Web of Science ®Google Scholar
• Samaei A, Nobahar M, Vafaei AA. An experimental design for finding of minimum dosage of carbamazepine and valproate in preventing of seizure attacks. Pak J Pharm Sci 2009;22(2):180-3
   PubMed Web of Science ®Google Scholar